Tetrilune 50 mg, 300 mg, 25 mg Tablet
PDF Leaflet Revision Date: 04 July 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HIV-1 infection in adults and children u226540 kg.
Dosage (summary)
One tablet once daily, with or without food.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; potential risk of neural tube defects.
Key Drug Interactions
- Dofetilide (contraindicated)
- Metformin (contraindicated)
- Etravirine (decreased dolutegravir levels)
Contraindications
- Hypersensitivity to components
- Severe renal impairment
- Severe hepatic impairment
- Pregnancy and lactation
Common side effects
- Nausea
- Diarrhoea
- Fatigue
- Rash
- Neutropenia
Counselling Points
- Monitor for signs of lactic acidosis.
- Regular liver function tests recommended.
- Use effective contraception in women of childbearing potential.
Serious warnings
- Lactic acidosis
- Severe hepatotoxicity
- Immune reconstitution inflammatory syndrome (IRIS)
Important Disclaimer
The Tetrilune 50 mg, 300 mg, 25 mg Tablet professional information leaflet below is the property of Cipla Medpro and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
